

# USE OF ON-DEMAND TREATMENTS FOR OFF EPISODES IN PARKINSON'S DISEASE: GUIDANCE FROM A RAND/UCLA MODIFIED DELPHI CONSENSUS PANEL

Stuart H. Isaacson, MD<sup>1</sup>, Madhureeta Achari, MD<sup>2</sup>, Roongroj Bhidayasiri, MD<sup>3</sup>, Cynthia Comella, MD, FAAN<sup>4</sup>, Jill Giordano Farmer, DO, MPH<sup>5</sup>, Fiona Gupta, MD<sup>6</sup>, Sarah Jones, MPA, MS<sup>7</sup>, David Kreitzman, MD<sup>8</sup>, Daniel Kremens, MD, JD, FAAN<sup>9</sup>, Simon Lewis, MBBCh, BSc, FRCP, FRACP, MD<sup>10</sup>, Werner Poewe, MD<sup>11</sup>, Eduardo Tolosa, MD, PhD<sup>12</sup>, Cynthia Campos, MPH<sup>13</sup>, Irina Yermilov, MD, MPH, MS<sup>13</sup>, Michael S. Broder, MD, MSHS<sup>13</sup>

<sup>1</sup>Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA; <sup>2</sup>Integrated Neurology PA, Department of Physical Medicine and Rehabilitation, University of Texas, McGovern Medical School, Houston, TX, USA; <sup>3</sup>Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; <sup>4</sup>Department of Neurosurgery and Neurological Sciences, Rush University Medical Center, Chicago, IL, USA; <sup>5</sup>Global Parkinson's Disease & Movement Disorder Program, Global Neurosciences Institute and Drexel College of Medicine, Philadelphia, PA, USA; <sup>6</sup>Department of Neurology, Mount Sinai Medical Center, Mount Sinai Beth Israel Morningside, Mount Sinai West, The Mount Sinai Hospital, New York, NY, USA; <sup>7</sup>Parkinson's & Movement Disorder Alliance, Tucson, AZ, USA; <sup>8</sup>Parkinson's Disease and Movement Disorders Center of Long Island, Commack, NY, USA; <sup>9</sup>Department of Neurology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA; <sup>10</sup>Brain and Mind Centre, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia; <sup>11</sup>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; <sup>12</sup>Parkinson's Disease Research Program, University of Barcelona, Barcelona, Spain; <sup>13</sup>Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA, USA

## BACKGROUND

- Patients with Parkinson's disease (PD) on levodopa develop motor fluctuations and often experience OFF episodes with reemerging parkinsonian symptoms throughout the day despite regular medication use
- On-demand treatments are designed to provide rapid onset of effect to treat OFF episodes and improve symptoms. However, there is little guidance on how best to use these treatments

## OBJECTIVE

- Develop consensus on the use of on-demand treatments (levodopa inhalation powder, apomorphine sublingual film, and apomorphine subcutaneous injection) for OFF episodes in patients with PD

## METHODS

- We conducted an expert RAND/UCLA Delphi panel (**Figure 1**)
  - We convened an international panel of experts (11 clinicians, 1 patient advocate) and reviewed evidence on the use of on-demand treatments for OFF episodes. Eight panelists were from the United States (US) and 4 were from outside the US.
  - We collaboratively developed a rating form consisting of 432 unique patient scenarios that varied based on 6 key characteristics (**Table 1**).
  - Before and after a virtual meeting, panelists rated the appropriateness of prescribing on-demand treatments.
  - At the meeting, panelists discussed areas of disagreement.
- After the meeting, consensus statements summarizing the group opinion were drafted.

**Figure 1. The RAND/UCLA Delphi panel process**



**Table 1. Clinical characteristics used to inform patient scenarios**

Clinical characteristic	Categories and definitions
Patient's perspective on the functional impact of OFF episodes	<ul style="list-style-type: none"> <li>Not interfering with daily activities, but may impact life in other ways<sup>a</sup></li> <li>Interfering with some instrumental daily activities<sup>b</sup></li> <li>Disabling/interfering with most basic daily activities<sup>c</sup></li> </ul>
Levodopa dose	<ul style="list-style-type: none"> <li>Low: total daily dose &lt;400mg or ≤3/day</li> <li>Medium: total daily dose 400-600mg or 4-5/day</li> <li>High: total daily dose &gt;600mg or ≥6/day</li> </ul>
Adjunctive therapies (i.e., ON-extendors)	<ul style="list-style-type: none"> <li>No adjunctive therapies</li> <li>A dopamine receptor agonist and possibly other adjunctive therapies</li> <li>Any other adjunctive therapies excluding dopamine receptor agonists</li> </ul>
Experiencing therapy-related side effects <sup>d</sup>	<ul style="list-style-type: none"> <li>No</li> <li>Yes, including very likely to experience side effects if dose was increased</li> </ul>
Frequency or duration of OFF episodes	<ul style="list-style-type: none"> <li>Frequent/long duration: ≥2 times/week for early morning OFF, ≥3 times/day or &gt;25% of waking day for other types of OFF</li> <li>Less frequent/shorter duration: ≤1 time/week for early morning OFF, ≤2 times/day or ≤25% of waking day for other types of OFF</li> </ul>
Type of OFF episodes	<ul style="list-style-type: none"> <li>Wearing OFF (i.e., the reemergence of parkinsonian symptoms as the effect of levodopa diminishes near the end of the dose interval)</li> <li>Early morning OFF (i.e., morning slowness or immobility experienced prior to the first medication dose of the day may also include nocturnal OFF)</li> <li>Delayed ON (i.e., failure to turn ON following a dose of levodopa, resulting in a delayed ON, dose failure, or no ON response)</li> <li>&gt;1 type/not described by other categories<sup>e</sup></li> </ul>

<sup>a</sup>Although patient's daily activities are not affected, the OFF episodes do impact their lives in other ways (e.g., fear/reluctance to leave home, decreased job performance).  
<sup>b</sup>For example, driving, shopping, cooking, traveling, remembering to take medication, managing finances.  
<sup>c</sup>For example, hygiene, self-care, feeding, safety.  
<sup>d</sup>Side effects may include an intolerance to levodopa (e.g., nausea, sleepiness/fatigue, symptomatic low blood pressure), other dopaminergic side effects (e.g., troublesome dyskinesia, paranoia, hallucinations), and/or dopaminergic dysregulation syndrome or impulse control disorders (as defined by the Diagnostic and Statistical Manual of Mental Disorders-5 [<https://dsm.psychiatryonline.org/doi/10.1176/appi.books.9780890425596.dsm15>]) that have a marked impact on the patient and cannot be monitored.  
<sup>e</sup>This may include unpredictable or unexpected OFF.

## RESULTS

- Overall, experts agreed that 230 (53%) scenarios were appropriate and 21 (5%) were inappropriate settings to prescribe on-demand treatments. Experts disagreed on 140 (32%) and were uncertain of 41 (9%) scenarios
- The panel endorsed the use of on-demand treatment for OFF episodes in the scenarios listed in **Table 2**
- Among panelists from the US, the group agreed that 62% of scenarios were appropriate settings to prescribe on-demand treatment

**Table 2. Expert recommendations on when it is appropriate to prescribe on-demand treatments for OFF episodes**

Functional impact of OFF episodes on daily activities	Expert recommendation on appropriateness of prescribing on-demand treatments for the patient to take as needed
OFF episodes are disabling and interfere with most basic daily activities	Appropriate in most circumstances
OFF episodes interfere with some instrumental daily activities	Appropriate if the patient also experiences <b>any</b> of the following: <ul style="list-style-type: none"> <li>Early morning OFF episodes or &gt;1 type of OFF episode (regardless of frequency)</li> <li>Frequent/long duration delayed ON episodes, except if the patient is on low-/medium-dose levodopa without any other adjunctive therapies (i.e., ON-extendors)</li> <li>Frequent/long duration wearing OFF episodes, except if the patient is on levodopa without any other adjunctive therapies</li> <li>Less frequent/shorter wearing OFF episodes and are on high-dose levodopa with an adjunctive treatment</li> </ul>
OFF episodes do not interfere with daily activities but can impact patient in other ways	Appropriate if the patient also meets <b>all</b> of the following: <ul style="list-style-type: none"> <li>Frequent early morning OFF, delayed ON, or &gt;1 type of OFF episode</li> <li>On high-dose levodopa and other adjunctive treatment (other than a dopamine receptor agonist)</li> <li>Therapy-related side effects</li> </ul>

## CONCLUSIONS

- Panelists agreed that on-demand treatment is appropriate for many patients with PD patients and OFF episodes
- The greater the functional impact of OFF episodes, the more likely panelists were in agreement that on-demand treatment is appropriate to prescribe
- In a few circumstances, panelists rated on-demand treatment as inappropriate; generally, these were in patients who experienced predictable wearing OFF episodes that had minimal functional impact and were on low- or medium-dose levodopa without adjunctive therapies
- In the US, 3 on-demand treatments are available; internationally, only 1 on-demand treatment (apomorphine subcutaneous injection) is commercially available. Although agreement was higher when considering only US panelists, the pattern of agreement (i.e., more agreement with greater functional impact) remained the same compared with the entire panel
- These recommendations may serve as one of the first guidelines to support clinicians in the appropriate use of on-demand treatments in patients with PD

## LIMITATIONS

- Although all panelists had significant experience in the field and were drawn from a diversity of backgrounds and geographic regions, 12 experts cannot represent the full experience of clinicians who work in this field. Different groups of experts may have reached different conclusions
- These results do not identify the scenarios in which each individual on-demand treatment (levodopa inhalation powder, apomorphine sublingual film, apomorphine subcutaneous injection) would be most appropriate